Manchester, England: Synexus has just concluded its fourth Phase II study for a major pharmaceutical client in the last two years. Synexus, which ran and managed the entire hypertension trial, completed the study in nine rather than the projected twelve months. Commenting on the increasing success of their unique model for clinical trials, CEO Michael Fort said: “We handle the whole process. Our clients have only one contract to negotiate and agree, then we get the trial process underway immediately-making sure that we reach the critical targets for our clients efficiently and quickly.”
A global leader in the recruitment of patients to its own research centres, Synexus used only four of its sixteen sites to conduct the trial involving 450 patients, slashing monitoring costs as well as recruitment timings. Sites in the UK, South Africa and Eastern Europe were central to Synexus ability to cut the forecast timings by 25% meaning the pharma reached the commercially critical go,no-go decision stage of their drug development programme far more rapidly than using the traditional Phase II trial model.
Michael Fort explains how time and cost efficiencies are achieved: “We are able to recruit the right types of patients quickly using our extensive database to help us identify suitable candidates. We combine this with a carefully targeted marketing campaign to ensure we reach the required number of patients as rapidly as possible. On this occasion we achieved the agreed 450 patients even more quickly than we had anticipated.”
Synexus are currently undertaking feasibility studies for further Phase II trials in a wide variety of therapeutic areas.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Zenocutuzumab Shows Durable Efficacy in NRG1 Fusion-Positive Cancers in Phase II eNRGy Trial
February 13th 2025The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 fusion–positive cancers, particularly non-small cell lung cancer and pancreatic cancer.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.